Brief: Kala Pharmaceuticals Receives FDA Fast Track Designation For KPI-012

KALA BIO

12/04/2023 14:01

April 12 (Reuters) - Kala Pharmaceuticals Inc  KALA.O :
    * KALA PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION
FOR
KPI-012, A HUMAN MSC-S THERAPY FOR PERSISTENT CORNEAL EPITHELIAL
DEFECT
    * KALA PHARMACEUTICALS INC - TARGETING REPORTING TOPLINE
SAFETY
AND EFFICACY DATA IN Q1 OF 2024  FOR KPI-012 TRIAL

Source text for Eikon:  ID:nGNXbq90dV 
Further company coverage:  KALA.O 

 ((Reuters.Briefs@thomsonreuters.com;;))